Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.
Year: 2006
Type: article
Source: PubMed
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: bevacizumab, metastatic colorectal cancer, vascular endothelial growth factor, angiogenesis inhibition, irinotecan, FOLFIRI, FOLFOX4, oxaliplatin, first-line chemotherapy, second-line chemotherapy, survival outcomes, adverse drug reactions, cardiotoxicity, hematologic toxicity, cost-effectiveness
Open Access status: closed
OpenAlex ID: W4298029361
